Literature DB >> 2427580

Generation of cytotoxic cells from murine bone marrow by human recombinant IL 2.

G C Koo, C L Manyak.   

Abstract

Murine bone marrow (BM) cells were cultured in recombinant IL 2 (rIL 2) and interferon-alpha, -beta, and -gamma, and cytotoxic activity against YAC cells was determined in a 4-hr 51Cr-release assay. rIL 2 at 20 U/ml was the only lymphokine that consistently induced significant cytotoxic activity within 3 days of culture, peaking around 5 to 7 days. The cytotoxic cells generated are heterogeneous, consisting of at least two populations of cells: a) NK-1+, Qa-5+, AsGm-1+ Thy-1+/-, Lyt-2- cells, similar to natural killer (NK) cells, and b) NK-1-, Qa-5+, AsGm-1+ Thy-1+, Lyt-2+ cells, similar to cytotoxic T lymphocytes. The precursor/accessory cells of these BM cytolytic cells maintained in 20 U/ml of rIL 2 were Qa-2+, Qa-5+, Thy-1+/-, AsGM-1+/-, and NK-1+/- but Lyt-2-. They also lysed NK-resistant targets, P815 and BW5147, and the antigenic phenotypes of these cells were similar to those that lysed YAC cells. These studies indicate that IL 2 alone is adequate to generate cytotoxic activity from BM and that these cytotoxic cells were similar to splenic NK cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427580

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Sequential activation of hormone/cytokines in the stimulation of NK cells: A new model of neuroendocrine-immune interaction.

Authors:  M Provinciali; N Fabris
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  Induction of tumoricidal macrophages from bone marrow cells of normal mice or mice bearing a colony-stimulating-factor-producing tumor.

Authors:  S Hosoe; T Ogura; S Hayashi; K Komuta; T Ikeda; T Shirasaka; I Kawase; T Masuno; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Endogenously secreted IL-4 is required for mouse thymocytes to become cytotoxic. Human, but not mouse, IL-2 induces a functionally immature thymic subset to secrete IL-4 and become CTL.

Authors:  K E Stedman; L B Justement; P A Campbell
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

4.  Natural killer (NK) cell activity in human long-term bone marrow cultures (LTBMC): effects of interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on the progenitor cells.

Authors:  E Sitnicka; M Hansson
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

Review 5.  Murine natural killer cell differentiation: past, present, and future.

Authors:  T A Moore; M Bennett; V Kumar
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

6.  Antiviral effect of lymphokine-activated killer cells: characterization of effector cells mediating prophylaxis.

Authors:  J F Bukowski; H Yang; R M Welsh
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  Antiviral effect of lymphokine-activated killer cells: chemotaxis and homing to sites of virus infection.

Authors:  R J Natuk; J F Bukowski; J O Brubaker; R M Welsh
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Natural health products, modulation of immune function and prevention of chronic diseases.

Authors:  Pierre S Haddad; Georges A Azar; Simon Groom; Michel Boivin
Journal:  Evid Based Complement Alternat Med       Date:  2005-10-20       Impact factor: 2.629

9.  Cooperative effects of colony-stimulating factor 1 and recombinant interleukin 2 on proliferation and induction of cytotoxicity of macrophage precursors generated from mouse bone marrow cell cultures.

Authors:  H Li; R Schwinzer; M Baccarini; M L Lohmann-Matthes
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

10.  The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures.

Authors:  M R van den Brink; S S Boggs; R B Herberman; J C Hiserodt
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.